Δ9-Tetrahydrocannabinol prevents methamphetamine-induced neurotoxicity

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Castelli, M Paola ^a   Madeddu, Camilla ^a   Casti, Alberto ^a   Casu, Angelo ^a   Casti, Paola ^a   Scherma, Maria ^a   Fattore, Liana ^b   Fadda, Paola ^a   Ennas, M Grazia ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID 1 RECEPTOR; DRONABINOL; GLIAL FIBRILLARY ACIDIC PROTEIN; METHAMPHETAMINE; NEURONAL NITRIC OXIDE SYNTHASE; RIMONABANT; CENTRAL STIMULANT AGENT; NEUROPROTECTIVE AGENT;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; ASTROCYTOSIS; BODY TEMPERATURE; BODY WEIGHT; BRAIN DAMAGE; CAUDATE NUCLEUS; CONTROLLED STUDY; MALE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PREFRONTAL CORTEX; PUTAMEN; RAT; ANIMAL; BRAIN; DRUG EFFECTS; METABOLISM; NERVE CELL; TOXICITY;

ANIMALS; BODY TEMPERATURE; BODY WEIGHT; BRAIN; CENTRAL NERVOUS SYSTEM STIMULANTS; DRONABINOL; MALE; METHAMPHETAMINE; NEURONS; NEUROPROTECTIVE AGENTS; NITRIC OXIDE SYNTHASE TYPE I; RATS;

EID: 84901294065     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0098079     Document Type: Article

References (72)

1. Maxwell JC, Brecht ML (2011) Methamphetamine: here we go again? Addict Behav 36: 1168-1173.
2. United Nation Office on Drugs and Crime (UNODC) (2013) World Drug Report 2013 (United Nations publication, Sales No. E.13.XI.6).
3. Krasnova IN, Cadet JL (2009) Methamphetamine toxicity and messengers of death. Brain Res Rev 60: 379-407.
4. Yamamoto BK, Moszczynska A, Gudelsky GA (2010) Amphetamine toxicities: classical and emerging mechanisms. Ann N Y Acad Sci 1187:101-121.
5. LaVoie MJ, Card JP, Hastings TG (2004) Microglial activation precedes dopamine terminal pathology in methamphetamine-induced neurotoxicity. Exp Neurol 187: 47-57. (Pubitemid 38470011)
6. Thomas DM, Dowgiert J, Francescutti-Verbeem D, Liu X, Kuhn DM (2004) Microglial is a pharmacologically specific marker for the neurotoxic amphetamines. Neurosci Lett 367: 349-354. (Pubitemid 39178611)
7. Davidson C, Gow AJ, Lee TH, Ellinwood EH (2001) Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brain Res Brain Res Rev 36: 1-22. (Pubitemid 32763126)
8. Marshall JF, O'Dell SJ (2012) Methamphetamine influences on brain and behavior: unsafe at any speed? Trends Neurosci 35: 536-545.
9. Simon SL, Domier CP, Sim T, Richardson K, Rawson RA, et al. (2002) Cognitive performance of current methamphetamine and cocaine abusers. J Addict Dis 21: 61-74. (Pubitemid 35203854)
10. Gonzalez R, Rippeth JD, Carey CL, Heaton RK, Moore DJ, et al. (2004) Neurocognitive performance of methamphetamine users discordant for history of marijuana exposure. Drug Alcohol Depend 76: 181-190. (Pubitemid 39370814)
11. Sarne Y, Asaf F, Fishbein M, Gafni M, Keren O (2011) The dual neuroprotective-neurotoxic profile of cannabinoid drugs. Br J Pharmacol 163: 1391-401.
12. Fowler CJ, Rojo ML, Rodriguez-Gaztelumendi A (2010) Modulation of the endocannabinoid system: neuroprotection or neurotoxicity? Exp Neurol 224: 37-47.
13. Pope C, Mechoulam R, Parsons L (2010) Endocannabinoid signaling in neurotoxicity and neuroprotection. Neurotoxicology 31: 562-571.
14. Voytek B, Berman SM, Hassid BD, Simon SL, Mandelkern MA, et al. (2005) Differences in regional brain metabolism associated with marijuana abuse in methamphetamine abusers. Synapse 57: 113-115. (Pubitemid 40911526)
15. Sung YH, Carey PD, Stein DJ, Ferrett HL, Spottiswoode BS, et al. (2013) Decreased frontal N-acetylaspartate levels in adolescents concurrently using both methamphetamine andmarijuana. Behav Brain Res. 246: 154-161.
16. Churchwell JC, Carey PD, Ferrett HL, Stein DJ, Yurgelun-Todd DA (2012) Abnormal striatal circuitry and intensified novelty seeking among adolescents who abuse methamphetamine and cannabis. Dev Neurosci. 34: 310-317.
17. Landa L, Sulcova A, Slais K (2006) Involvement of cannabinoid CB1 and CB2 receptor activity in the development of behavioural sensitization to methamphetamine effects in mice. Neuro Endocrinol Lett. 27: 63-69. (Pubitemid 43970768)
18. 1 cannabinoid receptors. J Psychiatr Res 44: 944-955.
19. Fernández-Ruiz J, García C, Sagredo O, Gómez-Ruiz M, de Lago E (2010) The endocannabinoid system as a target for the treatment of neuronal damage. Expert Opin Ther Targets 14: 387-404.
20. Nagayama T, Sinor AD, Simon RP, Chen J, Graham SH, et al. (1999) Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J Neurosci 19: 2987-2995. (Pubitemid 29173995)
21. Hampson AJ, Grimaldi M (2001) Cannabinoid receptor activation and elevated cyclic AMP reduce glutamate neurotoxicity. Eur J Neurosci 13: 1529-1536. (Pubitemid 32423339)
22. Panikashvili D, Simeonidou C, Ben-Shabat S, Hanus L, Breuer A, et al. (2001) An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 413: 527-533.
23. Marsicano G, Moosmann B, Hermann H, Lutz B, Behl C (2002) Neuroprotective properties of cannabinoids against oxidative stress: role of the cannabinoid receptor CB1. J Neurochem 80: 448-456. (Pubitemid 36383028)
24. Bisogno T, Di Marzo V (2008) The role of the endocannabinoid system in Alzheimer's disease: facts and hypotheses. Curr Pharm Des 14: 2299-3305.
25. García-Arencibia M, García C, Fernández-Ruiz J (2009) Cannabinoids and Parkinson's disease. CNS Neurol Disord Drug Targets 8: 432-439.
26. Valdeolivas S, Satta V, Pertwee RG, Fernández-Ruiz J, Sagredo O (2012) Sativex-like Combination of Phytocannabinoids is Neuroprotective in Malonate-Lesioned Rats, an Inflammatory Model of Huntington's Disease: Role of CB(1) and CB(2) Receptors. ACS Chem Neurosci 16: 400-406.
27. Baker D, Pryce G (2008) The endocannabinoid system and multiple sclerosis. Curr Pharm Des 14: 2326-2336.
28. Mechoulam R, Shohami E (2007) Endocannabinoids and traumatic brain injury. Mol Neurobiol 36: 68-74. (Pubitemid 351360359)
29. Deng X, Cadet JL (1999) Methamphetamine administration causes overexpression of nNOS in the mouse striatum. Brain Res 851: 254-257. (Pubitemid 30038153)
30. Anderson KL, Itzhak Y (2006) Methamphetamine-induced selective dopaminergic neurotoxicity is accompanied by an increase in striatal nitrate in the mouse. Ann N Y Acad Sci 1074: 225-233. (Pubitemid 44532826)
31. Ayata C, Ayata G, Hara H, Matthews RT, Beal MF, et al. (1997) Mechanisms of reduced striatal NMDA excitotoxicity in type I nitric oxide synthase knock-out mice. J Neurosci 15: 6908-6917. (Pubitemid 27427869)
32. Imam SZ, Newport GD, el-Yazal J, Itzhak Y, Cadet JL, et al. (2001) Peroxynitrite plays a role in methamphetamine-induced dopaminergic neurotoxicity: evidence from mice lacking neuronal nitric oxide sinthase gene or overexpressing copper-zinc superoxide dismutase. J Neurochem 76: 745-749. (Pubitemid 32126074)
33. Kim SH, Won SJ, Mao XO, Ledent C, Jin K, et al. (2006) Role for neuronal nitric-oxide synthase in cannabinoid-induced neurogenesis. J Pharmacol Exp Ther 319: 150-154. (Pubitemid 44455119)
34. Oddi S, Latini L, Viscomi MT, Bisicchia E, Molinari M, et al. (2012) Distinct regulation of nNOS and iNOS by CB2 receptor in remote delayed neurodegeneration. J Mol Med (Berl) 90: 371-387.
35. Morley KC, Li KM, Hunt GE, Mallet PE, McGregor IS (2004) Cannabinoids prevent the acute hyperthermia and partially protect against the 5-HT depleting effects of MDMA("Ecstasy") in rats. Neuropharmacology 46: 954-65. (Pubitemid 38471949)
36. Touriño C, Zimmer A, Valverde O (2010) THC Prevents MDMA Neurotoxicity in Mice. PLoS One 5: e9143.
37. Paxinos G, Watson C (1997) The rat brain in stereotaxic coordinates. San Diego: Academic Press, 3rd ed.
38. Bredt DS, Snyder SH (1990) Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme. Proc Natl Acad Sci U S A 87: 682-685.
39. Itzhak Y, Martin JL, Ail SF (2000) nNOS inhibitors attenuate methamphetamine-induced dopaminergic neurotoxicity but not hyperthermia in mice. Neuroreport 11: 2943-2946.
40. Callahan BT, Ricaurte GA (1998) Effect of 7-nitroindazole on body temperature and methamphetamine-induced dopamine toxicity. Neuroreport 9: 2691-2695. (Pubitemid 28435146)
41. El-Remessy AB, Khalil IE, Matragoon S, Abou-Mohamed G, Tsai NJ, et al. (2003) Neuroprotective effect of (-) Delta9-tetrahydrocannabinol and cannabidiol in N-methyl-D-aspartate-induced retinal neurotoxicity: involvement of peroxynitrite. Am J Pathol 163: 1997-2008. (Pubitemid 37310030)
42. Kim SH, Won SJ, Mao XO, Jin K, Greenberg DA (2006) Molecular mechanisms of cannabinoid protection from neuronal excitotoxicity. Mol Pharmacol 69: 691-696. (Pubitemid 43363843)
43. Ortega-Gutiérrez S, Molina-Holgado E, Guaza C (2005) Effect of anandamide uptake inhibition in the production of nitric oxide and in the release of cytokines in astrocyte cultures. Glia 52:163-168. (Pubitemid 41652920)
44. Asanuma M, Tsuji T, Miyazaki I, Miyoshi K, Ogawa N (2003) Methamphetamine-induced neurotoxicity in mouse brain is attenuated by ketoprofen, a nonsteroidal anti-inflammatory drug. Neurosci Lett 352: 13-16. (Pubitemid 37412314)
45. Gonçalves J, Baptista S, Martins T, Milhazes N, Borges F, et al. (2010) Methamphetamine-induced neuroinflammation and neuronal dysfunction in the mice hippocampus: preventive effect of indomethacin. Eur J Neurosc 31: 315-326.
46. Bortolato M, Frau R, Piras AP, Luesu W, Bini V, et al. (2009) Methamphetamine induces long-term alterations in reactivity to environmental stimuli: correlation with dopaminergic and serotonergic toxicity. Neurotox Res 15(3):232-45
47. Wang J, Angulo JA (2011) Synergism between methamphetamine and the neuropeptide substance P on the production of nitric oxide in the striatum of mice. Brain Res 1369: 131-139.
48. Blackshaw S, Eliasson MJ, Sawa A, Watkins CC, Krug D, et al. (2003) Species, strain and developmental variations in hippocampal neuronal and endothelial nitric oxide synthase clarify discrepancies in nitric oxide-dependent synaptic plasticity. Neuroscience 119: 979-990. (Pubitemid 36776448)
49. Massi P, Valenti M, Bolognini D, Parolaro D (2008) Expression and function of the endocannabinoid system in glial cells. Curr Pharm Des 14: 2289-2298.
50. Gruber SA, Rogowska J, Yurgelun-Todd DA (2009) Altered affective response in marijuana smokers: an FMRI study. Drug Alcohol Depend 105: 139-53.
51. Patton GC, Coffey C, Carlin JB, Degenhardt L, Lynskey M, et al. (2002) Cannabis use and mental health in young people: cohort study. BMJ 325: 1195-1198. (Pubitemid 35398781)
52. Cohen M, Rasser PE, Peck G, Carr VJ, Ward PB, et al. (2012) Cerebellar grey-matter deficits, cannabis use and first-episode schizophrenia in adolescents and young adults. Int J Neuropsychopharmacol 15: 297-307.
53. Solowij N, Yucel M, Respondek C, Whittle S, Lindsay E, et al. (2011) Cerebellar white-matter changes in cannabis users with and without schizophrenia. Psychol Med 41: 2349-2359.
54. O'Shea M, McGregor IS, Mallet PE (2006) Repeated cannabinoid exposure during perinatal, adolescent or early adult ages produces similar longlasting deficits in object recognition and reduced social interaction in rats. J Psychopharmacol 20: 611-621. (Pubitemid 44315859)
55. Rubino T, Realini N, Braida D, Alberio T, Capurro V, et al. (2009) The depressive phenotype induced in adult female rats by adolescent exposure to THC is associated with cognitive impairment and altered neuroplasticity in the prefrontal cortex. Neurotox Res 15: 291-302.
56. Lawston J, Borella A, Robinson JK, Whitaker-Azmitia PM (2000) Changes in hippocampal morphology following chronic treatment with the synthetic cannabinoid WIN 55,212-2. Brain res 877: 407-410.
57. Fishbein M, Gov S, Assaf F, Gafni M, Keren O, et al. (2012) Long-term behavioral and biochemical effects of an ultra-low dose of Δ9- tetrahydrocannabinol (THC): neuroprotection and ERK signaling. Exp Brain Res 221: 437-448.
58. Fernández-Ruiz J, Pazos MR, García-Arencibia M, Sagredo O, Ramos JA (2008) Role of CB2 receptors in neuroprotective effects of cannabinoids. Mol Cell Endocrinol 286 (1-2 Suppl 1): S91-6.
59. Pacher P, Mechoulam R (2011) Is lipid signaling through cannabinoid 2 receptors part of a protective system? Prog Lipid Res 50: 193-211.
60. Torres E, Gutierrez-Lopez MD, Borcel E, Peraile I, Mayado A, et al. (2010) Evidence that MDMA ('ecstasy') increases cannabinoid CB2 receptor expression in microglial cells: role in the neuroinflammatory response in rat brain. J Neurochem 113: 67-78.
61. Hansen HH, Azcoitia I, Pons S, Romero J, García-Segura LM, et al. (2002) Blockade of cannabinoid CB(1) receptor function protects against in vivo disseminating brain damage following NMDA-induced excitotoxicity. J Neurochem 82: 154-158. (Pubitemid 34755260)
62. Pellegrini-Giampietro DE, Mannaioni G, Bagetta G (2009) Post-ischemic brain damage: the endocannabinoid system in the mechanisms of neuronal death. FEBS J 276:2-12.
63. Muthian S, Rademacher DJ, Roelke CT, Gross GJ, Hillard CJ (2004) Anandamide content is increased and CB1 cannabinoid receptor blockade is protective during transient, focal cerebral ischemia.Neuroscience 129: 743-50. (Pubitemid 39487125)
64. Amantea D, Spagnuolo P, Bari M, Fezza F, Mazzei C, et al. (2007) Modulation of the endocannabinoid system by focal brain ischemia in the rat is involved in neuroprotection afforded by 17beta-estradiol. FEBS J 274: 4464-4775.
65. Berger C, Schmid PC, Schabitz WR, Wolf M, Schwab S, et al. (2004) Massive accumulation of N-acylethanolamines after stroke. Cell signalling in acute cerebral ischemia? J Neurochem 88: 1159-1167. (Pubitemid 38280683)
66. Pegorini S, Zani A, Braida D, Guerini-Rocco C, Sala M (2006) Vanilloid VR1 receptor is involved in rimonabant-induced neuroprotection. Br J Pharmacol 147: 552-559. (Pubitemid 43355053)
67. Marinelli S, Vaughan CW, Christie MJ, Connor M (2002) Capsaicin activation of glutamatergic synaptic transmission in the rat locus coeruleus in vitro.J Physiol 543: 531-40. (Pubitemid 35012207)
68. De Petrocellis L, Davis JB, Di Marzo V (2001) Palmitoylethanolamide enhances anandamide stimulation of human vanilloid VR1 receptors. FEBS Lett 506: 253-256. (Pubitemid 32964824)
69. Cernak I, Vink R, Natale J, Stoica B, Lea PM 4th, et al. (2004) The "dark side" of endocannabinoids: a neurotoxic role for anandamide. J Cereb Blood Flow Metab 24: 564-578. (Pubitemid 38608289)
70. Hansen HS, Lauritzen L, Moesgaard B, Strand AM, Hansen HH (1998) Formation of N- acyl-phosphatidylethanolamines and N-acetylethanolamines: proposed role in neurotoxicity. Biochem Pharmacol 55: 719-725. (Pubitemid 28319635)
71. Köfalvi A, Vizi ES, Ledent C, Sperlágh B (2003) Cannabinoids inhibit the release of [3H] glutamate from rodent hippocampal synaptosomes via a novel CB1 receptor-independent action. Eur J Neurosci 18: 1973-1978.
72. Scott LA, Roxburgh A, Bruno R, Matthews A, Burns L (2012) The impact of comorbid cannabis and methamphetamine use on mental health among regular ecstasy users. Addict Behav 37: 1058-1062.